A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00187525

Enrollment

Unknown

Registered

2005-09-16

Start date

2004-05-31

Completion date

2006-10-31

Last updated

2012-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frontotemporal Lobar Degeneration

Brief summary

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Interventions

DRUGMemantine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Neary et al. Criteria for Frontotemporal Lobar Degeneration * Age 40 -80 * CDR \< 3 or MMSE \> 15 * English Speaking * Study Partner

Exclusion criteria

* Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026